

The Role of Glycemic Control in the Management of Erectile Dysfunction among Patients with Type 2 Diabetes

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Erectile dysfunction (ED) has been a common complication among men with type 2 diabetes mellitus (T2DM), affecting up to 75% of this population. The interplay between poor glycemic control and the development of ED was multifaceted, involving vascular impairment, neuropathy, hormonal imbalances, and oxidative stress. Chronic hyperglycemia contributed to endothelial dysfunction, reduced nitric oxide availability, and nerve damage, all of which negatively impact erectile function. Glycemic management, therefore, played a crucial role in both preventing and treating ED in diabetic patients. This review investigated the pathophysiological mechanisms linking hyperglycemia to ED, evaluates the impact of glycemic control on erectile function, and explored therapeutic strategies that integrate glycemic management with ED treatment. Comprehensively, analysis of recent clinical studies and reviews addressing the relationship between glycemic control and ED outcomes in diabetic patients were the methods utilized in assembling this paper. Findings suggested that tight glycemic control (HbA1c < 7.0%) not only reduces the incidence of ED but also enhanced the effectiveness of pharmacological treatments like phosphodiesterase type 5 (PDE5) inhibitors. Additionally, lifestyle modifications and testosterone replacement therapy (TRT) are beneficial in managing both T2DM and ED, particularly when combined with improved glycemic control. Future research should focus on personalized treatment protocols and emerging therapies to optimize outcomes for this population.

Keywords: Glycemic control, Erectile dysfunction, Type 2 diabetes mellitus (T2DM), Endothelial dysfunction, Phosphodiesterase type 5 (PDE5) inhibitors.

INTRODUCTION

Erectile dysfunction (ED) is a prevalent and distressing complication among men with type 2 diabetes mellitus (T2DM), affecting up to 75% of this population [1,2]. ED, characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance, is more common in men with diabetes and tends to develop at an earlier age compared to those without the disease [3,4]. The increased incidence of ED in diabetic patients is attributed to multiple factors, including vascular, neurological, and endocrine dysfunctions, all of which are exacerbated by poor glycemic control [5]. Chronic hyperglycemia plays a critical role in the development and progression of ED in patients with T2DM. Elevated blood glucose levels contribute to endothelial dysfunction, reduced nitric oxide availability, neuropathy, and hormonal imbalances, which collectively impair erectile function [6]. As such, effective glycemic

management is essential not only for the overall health of diabetic patients but also for preventing and managing ED [7,8]. Studies have shown that improved glycemic control can reduce the severity of ED, enhance the efficacy of pharmacological treatments, and potentially reverse some of the damage caused by chronic hyperglycemia [9,10]. This review aims to explore the relationship between glycemic control and ED in patients with T2DM. We will examine the pathophysiological mechanisms by which poor glycemic control contributes to ED, discuss the impact of glycemic management on ED outcomes, and evaluate the latest therapeutic approaches that integrate glycemic control with ED treatment. By synthesizing current research, this review will provide a comprehensive overview of how optimizing glycemic levels can improve erectile function in diabetic patients and highlight future directions for research in this area.

PATHOPHYSIOLOGY OF ERECTILE DYSFUNCTION IN TYPE 2 DIABETES

Erectile dysfunction in T2DM is a consequence of complex interactions between vascular, neurological, and hormonal factors, all of which are adversely affected by poor glycemic control

[11]. The following mechanisms highlight the key pathways by which hyperglycemia contributes to ED:

- i. **Endothelial Dysfunction and Vascular Impairment:** Diabetes-induced endothelial dysfunction is a primary cause of ED. Hyperglycemia damages endothelial cells, leading to impaired nitric oxide (NO) synthesis, a critical molecule for vasodilation and penile erection [12]. The reduced availability of NO decreases smooth muscle relaxation in the corpus cavernosum, resulting in insufficient blood flow for erection. Additionally, advanced glycation end-products (AGEs) accumulate in diabetic patients, further exacerbating vascular stiffness and reducing erectile function [13].
- ii. **Neuropathy:** Diabetic neuropathy affects both autonomic and somatic nerves involved in erectile function [14]. Hyperglycemia damages nerve fibers responsible for the transmission of signals necessary for penile erection. The autonomic nervous system, which regulates blood flow during sexual arousal, is particularly vulnerable to the effects of chronic high blood sugar, resulting in delayed or absent erections. Studies have shown that the severity of

- iii. **Testosterone Deficiency:** Men with T2DM often exhibit lower levels of testosterone, a condition known as hypogonadism, which can contribute to sexual dysfunction [17]. Hyperglycemia and insulin resistance have been associated with alterations in the hypothalamic-pituitary-gonadal axis, leading to reduced testosterone production [18]. Low testosterone exacerbates ED by decreasing libido and impairing penile tissue responsiveness to stimuli [19].
- iv. **Oxidative Stress and Inflammation:** Chronic hyperglycemia promotes oxidative stress and inflammation, both of which are key contributors to endothelial dysfunction [20]. Excess glucose leads to the overproduction of reactive oxygen species (ROS), damaging blood vessels and nerves. Additionally, systemic inflammation seen in T2DM patients can negatively affect erectile tissue, reducing its ability to respond to vasodilatory signals during sexual arousal [21-23].

GLYCEMIC CONTROL AND ITS IMPACT ON ERECTILE DYSFUNCTION

Several studies have shown that glycemic control is a modifiable risk factor for ED in diabetic men. Improved glycemic management has been associated with better erectile function and a lower risk of developing severe ED. The following sections outline the impact of glycemic control on ED outcomes:

- i. **Tight Glycemic Control and ED Prevention:** Research suggests that maintaining optimal glycemic control reduces the risk of ED by preserving vascular and nerve function [24]. For example, men with well-controlled diabetes (HbA1c < 7.0%) have significantly lower rates of ED compared to those with poor control (HbA1c > 9.0%). A landmark study demonstrated that intensive glycemic control reduced the incidence of ED by 35% in newly diagnosed diabetic patients. Early and sustained glycemic management may help prevent the onset of ED by reducing the cumulative damage to blood vessels and nerves [25].
- ii. **Reversing ED with Improved Glycemic Control:** In cases where ED has already

developed, improving glycemic control can lead to partial or full recovery of erectile function [1]. Studies have shown that men with T2DM who achieve significant reductions in HbA1c levels experience improvements in erectile performance [26]. One study found that diabetic men who reduced their HbA1c from 8.5% to 7.0% over a 12-month period reported better erectile function scores, as measured by the International Index of Erectile Function (IIEF). [27] This highlights the reversible nature of some of the vascular and neurological damage caused by hyperglycemia.

- iii. **Timing and Intensity of Glycemic Control:** While tight glycemic control is beneficial, overly aggressive glucose lowering in long-standing diabetes may not yield additional benefits for ED and could increase the risk of hypoglycemia, which can negatively impact sexual health [28]. A balanced approach, targeting an HbA1c of 7.0-8.0%, may provide optimal outcomes for erectile function while minimizing risks [29-31].

THERAPEUTIC STRATEGIES FOR ED IN DIABETIC PATIENTS: THE ROLE OF GLYCEMIC CONTROL

While achieving glycemic control is essential for managing ED in T2DM patients, it often needs to be complemented by other therapeutic approaches. These include:

- i. **Phosphodiesterase Type 5 (PDE5) Inhibitors:** PDE5 inhibitors, such as sildenafil (Viagra), are the first-line pharmacological treatment for ED [32]. These medications work by enhancing the

effects of NO, improving blood flow to the penis. Studies show that glycemic control can improve the efficacy of PDE5 inhibitors, as men with better-controlled blood sugar levels respond more favorably to these medications [33,34].

- ii. **Lifestyle Modifications:** Weight loss, increased physical activity, and dietary changes are crucial in managing both T2DM and ED [35]. Research indicates that men who adopt healthier lifestyles and achieve glycemic control experience significant improvements in erectile function. For example, a Mediterranean diet rich in fruits, vegetables, and healthy fats has been associated with better erectile performance in diabetic men [36].
- iii. **Testosterone Replacement Therapy (TRT):** For diabetic men with hypogonadism, testosterone replacement therapy may be beneficial in conjunction

- iv. **Emerging Therapies:** Newer therapies such as low-intensity extracorporeal shockwave therapy (LI-ESWT) and regenerative treatments, including stem cell therapy and platelet-rich plasma (PRP) injections, are being explored as potential treatments for ED in diabetic patients [39]. These therapies aim to repair vascular and nerve damage, offering a novel approach to ED management. Optimal glycemic control is likely to enhance the efficacy of these treatments, as healthier blood vessels and nerves respond better to regenerative therapies [40].

CONCLUSION

The relationship between glycemic control and erectile dysfunction in men with type 2 diabetes is well-established, with chronic hyperglycemia playing a central role in the development and progression of ED. Achieving and maintaining optimal glycemic control is essential for both preventing and managing ED in diabetic patients. While pharmacological and lifestyle interventions are important components of ED treatment, glycemic management remains the cornerstone for

improving sexual health in this population. Future research should focus on the long-term benefits of early glycemic control, explore the interaction between emerging ED therapies and glycemic status, and develop personalized treatment protocols that integrate glycemic management with novel therapeutic approaches. By addressing both diabetes and its sexual health complications, healthcare providers can enhance quality of life for patients with T2DM.

REFERENCES

1. Defeudis G, Mazzilli R, Tenuta M, Rossini G, Zamponi V, Olana S, Faggiano A, Pozzilli P, Isidori AM, Gianfrilli D. Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. *Diabetes Metab Res Rev.* 2022 Feb;38(2):e3494. doi: 10.1002/dmrr.3494. Epub 2021 Sep 21. PMID: 34514697; PMCID: PMC9286480.
2. Parmar RS, Verma S, Neelkamal, Pathak VK, Bhadoria AS. Prevalence of erectile dysfunction in Type 2 diabetes mellitus (T2DM) and its predictors among diabetic men. *J Family Med Prim Care.* 2022 Jul;11(7):3875-3879. doi: 10.4103/jfmpc.jfmpc_1130_21. Epub 2022 Jul 22. PMID: 36387626; PMCID: PMC9648286.
3. Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, Maggi M, Nelson CJ, Parish S, Salonia A, Tan R, Mulhall JP, Hellstrom WJ. Erectile dysfunction. *Nat Rev Dis Primers.* 2016 Feb 4; 2:16003. doi: 10.1038/nrdp.2016.3. PMID: 27188339; PMCID: PMC5027992.
4. Chapter 8 - Male pelvic floor dysfunctions and evidence-based physical therapy, Editor(s): Kari Bø, Bary Berghmans, Siv Mørkved, Marijke Van Kampen, Evidence-Based Physical Therapy for the Pelvic Floor (Second Edition), Churchill Livingstone, 2015, Pages 271-309, <https://doi.org/10.1016/B978-0-7020-4443-4.00008-X>.
5. Otto Appenzeller, Guillaume J. Lamotte, Elizabeth A. Coon, Chapter 8 - Neurogenic control of sexual function, Editor(s): Otto Appenzeller, Guillaume J. Lamotte, Elizabeth A. Coon, Introduction to Basic Aspects of the Autonomic Nervous System (Sixth Edition), Academic Press, 2022, Pp 423-465, <https://doi.org/10.1016/B978-0-323-95584-3.00001-4>.
6. Zeleke, M., Hailu, D. & Daka, D. Erectile dysfunction and associated factors among diabetic patients at, Hawassa, Southern, Ethiopia. *BMC Endocr Disord* 21, 139 (2021). <https://doi.org/10.1186/s12902-021-00807-5>
7. Cignarelli A, Genchi VA, D'Oria R, Giordano F, Caruso I, Perrini S, Natalicchio A, Laviola L, Giorgino F. Role of Glucose-Lowering Medications in Erectile Dysfunction. *J Clin Med.* 2021

- Jun 5;10(11):2501. doi: 10.3390/jcm10112501. PMID: 34198786; PMCID: PMC8201035.
8. Meza CA, La Favor JD, Kim D-H, Hickner RC. Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS? *International Journal of Molecular Sciences*. 2019; 20(15):3775. <https://doi.org/10.3390/ijms20153775>
 9. Goldney, J., Sargeant, J.A. & Davies, M.J. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. *Diabetologia* 66, 1832–1845 (2023). <https://doi.org/10.1007/s00125-023-05988-3>
 10. Afsheen Syeda, Daniel Battillo, Aayush Visaria, Steven K. Malin, The importance of exercise for glycemic control in type 2 diabetes, *American Journal of Medicine Open*, 2023, 9, 100031. <https://doi.org/10.1016/j.ajmo.2023.100031>.
 11. Tosur M, Viau-Colindres J, Astudillo M, *et al* Medication-induced hyperglycemia: pediatric perspective *BMJ Open Diabetes Research and Care* 2020;8:e000801. doi: 10.1136/bmjdr-2019-000801
 12. Poonosamy J, Lopes P, Huret P, Dardari R, Penfornis A, Thomas C, Dardari D. Impact of Intensive Glycemic Treatment on Diabetes Complications—A Systematic Review. *Pharmaceutics*. 2023; 15(7):1791. <https://doi.org/10.3390/pharmaceutics15071791>
 13. Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas, John B. Buse; Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 1 November 2022; 45 (11): 2753–2786. <https://doi.org/10.2337/dci22-003>
 14. Agochukwu-Mmonu N, Pop-Busui R, Wessells H, Sarma AV. Autonomic neuropathy and urologic complications in diabetes. *Auton Neurosci*. 2020 Dec; 229:102736. doi: 10.1016/j.autneu.2020.102736. Epub 2020 Oct 16. PMID: 33197694; PMCID: PMC10248950.
 15. Nnenaya Agochukwu-Mmonu, Rodica Pop-Busui, Hunter Wessells, Aruna V. Sarma, Autonomic neuropathy and urologic complications in diabetes, *Autonomic Neuroscience*, 2020; 229, 102736. <https://doi.org/10.1016/j.autneu.2020.102736>.
 16. Azmi S, Ferdousi M, Kalteniece A, et al. Diagnosing and managing diabetic somatic and autonomic neuropathy. *Therapeutic Advances in Endocrinology and Metabolism*. 2019;10. doi: [10.1177/2042018819826890](https://doi.org/10.1177/2042018819826890)
 17. Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu and Simeon Ikechukwu Egba (2023) Coexisting Conditions: Addressing Diabetes in Sickle Cell Anemia Care Int. J. Curr. Res. Med. Sci. (2023). 9(11): 23-28
 18. Hayek AA, Robert AA, Alshammari G, Hakami H, Al Dawish MA. Assessment of Hypogonadism in Men with Type 2 Diabetes: A Cross-Sectional Study from Saudi Arabia. *Clin Med Insights Endocrinol Diabetes*. 2017 May 19; 10:1179551417710209. doi: 10.1177/1179551417710209. Erratum in: *Clin Med Insights Endocrinol Diabetes*. 2017 Oct 10; 10:1179551417722086. doi: 10.1177/1179551417722086. PMID: 28579862; PMCID: PMC5439570.
 19. Ilpo Huhtaniemi, Chapter 15 - Lack of testosterone or hypogonadism, Editor(s): Ilpo Huhtaniemi, Good and Bad Testosterone, Academic Press, 2024. pp 223-234, <https://doi.org/10.1016/B978-0-443-13432-6.00021-6>.
 20. Meza CA, La Favor JD, Kim DH, Hickner RC. Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS? *Int J Mol Sci*. 2019 Aug 2;20(15):3775. doi: 10.3390/ijms20153775. PMID: 31382355; PMCID: PMC6696313.
 21. González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. *Int J Mol Sci*. 2023 May 27;24(11):9352. doi: 10.3390/ijms24119352. PMID: 37298303; PMCID: PMC10253853.
 22. An, Y., Xu, Bt., Wan, Sr. *et al*. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. *Cardiovasc Diabetol* 22, 237 (2023). <https://doi.org/10.1186/s12933-023-01965-7>
 23. Kaur, R., Kaur, M. & Singh, J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic

- strategies. *Cardiovasc Diabetol* **17**, 121 (2018). <https://doi.org/10.1186/s12933-018-0763-3>
24. Yachmaneni A Jr, Jajoo S, Mahakalkar C, Kshirsagar S, Dhole S. A Comprehensive Review of the Vascular Consequences of Diabetes in the Lower Extremities: Current Approaches to Management and Evaluation of Clinical Outcomes. *Cureus*. 2023 Oct 23;15(10):e47525. doi: 10.7759/cureus.47525. PMID: 38022307; PMCID: PMC10664734.
 25. Li, Y., Liu, Y., Liu, S. *et al.* Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. *Sig Transduct Target Ther* **8**, 152 (2023). <https://doi.org/10.1038/s41392-023-01400-z>
 26. Weinberg AE, Eisenberg M, Patel CJ, Chertow GM, Leppert JT. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. *J Sex Med*. 2013 Dec;10(12):3102-9. doi: 10.1111/jsm.12318. Epub 2013 Sep 9. PMID: 24010555; PMCID: PMC3891923.
 27. Setho Hadisuyatmana, James H. Boyd, Ferry Efendi, Gulzar Malik, Michael Bauer, Sonia Reisenhofer, Non-medical and non-invasive interventions for erectile dysfunction in men with type 2 diabetes mellitus: A scoping review, *Heliyon*, 2023; 9(5): e15778. <https://doi.org/10.1016/j.heliyon.2023.e15778>.
 28. Godfrey Ogochukwu Ezema, Ndukaku Yusuf Omeh, Egba Simeon Ikechukwu, Ejiofor C Agbo, Adachukwu Ada Ikeyiand Emmanuel Ifeanyi Obeagu (2023) Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia (2023) *Asian Journal of Dental and Health Sciences* 3(2):32-36
 29. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. *INOSR Scientific Research*. 2024; 11(1):63-71. <https://doi.org/10.59298/INOSRSR/2024/1.1.16371>
 30. Rodríguez-Gutiérrez R, Millan-Alanis JM, Barrera FJ, McCoy RG. Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes. *Curr Diab Rep*. 2021 Dec 13;21(12):63. doi: 10.1007/s11892-021-01433-0. PMID: 34902079; PMCID: PMC8693335.
 31. Wang, P., Huang, R., Lu, S. *et al.* HbA1c below 7 % as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. *Cardiovasc Diabetol* **14**, 124 (2015). <https://doi.org/10.1186/s12933-015-0285-1>
 32. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors in the Management of Erectile Dysfunction. *P T*. 2013 Jul;38(7):407-19. PMID: 24049429; PMCID: PMC3776492.
 33. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. *INOSR Scientific Research*. 2024; 11(1):63-71. <https://doi.org/10.59298/INOSRSR/2024/1.1.16371>
 34. ElHady AK, El-Gamil DS, Abdel-Halim M, Abadi AH. Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives. *Pharmaceuticals*. 2023; 16(9):1266. <https://doi.org/10.3390/ph16091266>
 35. Petroni ML, Brodosi L, Marchignoli F, Sasdelli AS, Caraceni P, Marchesini G, Ravaioli F. Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. *Nutrients*. 2021 Aug 10;13(8):2748. doi: 10.3390/nu13082748. PMID: 34444908; PMCID: PMC8401663.
 36. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. *Research Invention Journal of Research in Medical Sciences*. 2024; 3(2):38-49.
 37. Kumari K, Kumar R, Memon A, Kumari B, Tehrim M, Kumari P, Shehryar M, Islam H, Islam R, Khatri M, Kumar S, Kumar A. Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis. *Clin Pract*. 2023 Mar 20;13(2):454-469. doi: 10.3390/clinpract13020041. PMID: 36961066; PMCID: PMC10037582.
 38. Defeudis G, Maddaloni E, Rossini G, Di Tommaso AM, Mazzilli R, Di Palma P, Pozzilli P, Napoli N. Glycemic Variability in Subjects with Diabetes and Hypogonadism during Testosterone Replacement Treatment: A Pilot Study. *J Clin Med*. 2022 Sep 11;11(18):5333. doi: 10.3390/jcm11185333. PMID: 36142982; PMCID: PMC9505941.
 39. Campbell JD, Milenkovic U, Usta MF, Albersen M, Bivalacqua TJ. The good, bad, and the ugly of regenerative therapies for erectile dysfunction. *Transl Androl Urol*. 2020 Mar;9(Suppl 2):S252-

- S261. doi: 10.21037/tau.2019.10.06.
PMID: 32257866; PMID:
PMC7108995.
40. Wang B, Gao W, Zheng MY, Lin G,
Lue TF. Recent advances in stem cell
therapy for erectile dysfunction: a

narrative review. *Expert Opin Biol Ther.*
2023 Jan-Jun;23(6):565-573. doi:
10.1080/14712598.2023.2203811. Epub
2023 Apr 20. PMID: 37078259; PMID:
PMC10330142.

**CITE AS: Kato Jumba K. (2024). The Role of Glycemic Control in the Management of Erectile Dysfunction among Patients with Type 2 Diabetes. IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 9(2):20-25.
<https://doi.org/10.59298/IDOSR/JBCP/24/92.202500>**